Current estimates suggest that during the first 10 years of biosimilar availability, consumers could save as much as $250 Billion

The Biosimilars Council, a division of the Association for Accessible Medicines, formerly known as GPhA, who works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products, and will educate the public and patients about the safety and effectiveness of biosimilars.

What are biosimilars? Put simply, biosimilars are biologic medicines that are highly similar to a corresponding brand biologic. Biosimilars offer a safe, effective, and affordable alternative for patients. They are approved by the U.S. Food and Drug Administration (FDA) and improve patient access to life-saving medicines. 

Reports, videos, news sources, and more. Take some time to learn all about biosimilars and the benefits they offer US consumers.

Take a minute and learn all about biosimilars and our industry in an easy to digest format. The best part? It’s free.

We are always on the road advocating for biosimilars and invite you to join us. Check out the details for our next event and bring your friends.

It is time to stand up for affordable medicines that will reduce costs, improve quality of life, and provide increased access for America’s patients. 

Join our mailing list for up-to-date information and insights from our member organizations. 


Press Releases